ELEV — Elevation Oncology Share Price
0.000.00%
Last trade - 00:00- $20.31m
- -$41.74m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.34 | ||
| Price to Tang. Book | 0.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.07% | ||
| Return on Equity | -77.48% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 29th, 2019
- Public Since
- June 25th, 2021
- No. of Shareholders
- 9
- No. of Employees
- 34
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 59,223,728
- Address
- 101 Federal Street, Suite 1900, BOSTON, 02110
- Web
- https://elevationoncology.com/
- Phone
- +1 7163711125
- Auditors
- CohnReznick LLP
Upcoming Events for ELEV
Q1 2025 Elevation Oncology Inc Earnings Release
Elevation Oncology Inc Annual Shareholders Meeting
Q2 2025 Elevation Oncology Inc Earnings Release
Q3 2025 Elevation Oncology Inc Earnings Release
Similar to ELEV
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Elevation Oncology share price?
As of Today at 20:25 UTC, shares in Elevation Oncology are trading at $0.34. This share price information is delayed by 15 minutes.
How has the Elevation Oncology share price performed this year?
Shares in Elevation Oncology last closed at $0.34 and the price had moved by -90.23% over the past 365 days. In terms of relative price strength the Elevation Oncology share price has underperformed the S&P500 Index by -90.98% over the past year.
What are the analyst and broker recommendations for Elevation Oncology?
The overall consensus recommendation for Elevation Oncology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Elevation Oncology dividend yield?
Elevation Oncology does not currently pay a dividend.
Does Elevation Oncology pay a dividend?
Elevation Oncology does not currently pay a dividend.
When does Elevation Oncology next pay dividends?
Elevation Oncology does not currently pay a dividend.
How do I buy Elevation Oncology shares?
To buy shares in Elevation Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Elevation Oncology?
As of the previous close price of $0.34, shares in Elevation Oncology had a market capitalisation of $20.31m.
Where are Elevation Oncology shares listed?
Here are the trading details for Elevation Oncology:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ELEV
What kind of share is Elevation Oncology?
Based on an overall assessment of its quality, value and momentum Elevation Oncology is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Elevation Oncology share price forecast for 2025?
The analyst consensus target price for shares in Elevation Oncology is $2.05. That is 497.67% above the last closing price of $0.34.
Analysts covering Elevation Oncology currently have a consensus Earnings Per Share (EPS) forecast of -$0.66 for the next financial year.
Find out moreWhat is the trend in the Elevation Oncology share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Elevation Oncology. Over the past six months, its share price has underperformed the S&P500 Index by -44.04%.
As of the last closing price of $0.34, shares in Elevation Oncology were trading -47.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Elevation Oncology PE Ratio?
The Elevation Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Elevation Oncology?
Elevation Oncology's management team is headed by:
- Steven Elms - CHM
- Shawn Leland - CEO
- Tammy Furlong - VFN
- Amy Cavers - VPR
- Siera Talbott - VPR
- Colin Walsh - IND